|
Title
|
|
|
|
Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Chronic (neuro)inflammation plays an important role in many age-related central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson's disease and vascular dementia. Inflammation also characterizes many conditions that form a risk factor for these CNS disorders, such as physical inactivity, obesity and cardiovascular disease. Lipocalin 2 (Lcn2) is an inflammatory protein shown to be involved in different age-related CNS diseases, as well as risk factor conditions thereof. Lcn2 expression is increased in the periphery and the brain in different age-related CNS diseases and also their risk factor conditions. Experimental studies indicate that Lcn2 contributes to various neuropathophysiological processes of age-related CNS diseases, including exacerbated neuroinflammation, cell death and iron dysregulation, which may negatively impact cognitive function. We hypothesize that increased Lcn2 levels as a result of age-related risk factor conditions may sensitize the brain and increase the risk to develop age-related CNS diseases. In this review we first provide a comprehensive overview of the known functions of Lcn2, and its effects in the CNS. Subsequently, this review explores Lcn2 as a potential (neuro)inflammatory link between different risk factor conditions and the development of age-related CNS disorders. Altogether, evidence convincingly indicates Lcn2 as a key constituent in ageing and age-related brain diseases. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Ageing research reviews. - Baltimore, Md
| |
|
Publication
|
|
|
|
Clare
:
Elsevier ireland ltd
,
2021
| |
|
ISSN
|
|
|
|
1568-1637
| |
|
DOI
|
|
|
|
10.1016/J.ARR.2021.101414
| |
|
Volume/pages
|
|
|
|
70
(2021)
, 31 p.
| |
|
Article Reference
|
|
|
|
101414
| |
|
ISI
|
|
|
|
000684933600007
| |
|
Pubmed ID
|
|
|
|
34325073
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|